An Integrated Systems Biology Approach to Developing Mesenchymal Stem/Stromal Cell-derived Cellular Therapeutics

开发间充质干/基质细胞衍生细胞疗法的综合系统生物学方法

• 批准号: 478514-2015
• 负责人: Stanford, William
• 金额: $ 9.12万
• 依托单位: University of Ottawa
• 依托单位国家: 加拿大
• 项目类别: Collaborative Health Research Projects
• 财政年份: 2015
• 资助国家: 加拿大
• 起止时间: 2015-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=579572
• 关键词: Integrated; Systems; Biology; Approach; Developing

Mesenchymal stromal/stem cells (MSCs) have the unique ability to attenuate the immune system and therefore are being developed as a promising cellular therapeutic to treat diverse immune and inflammatory disorders such as septic shock, multiple sclerosis and heart attacks. The efficacy or potency of MSCs is variable and the lack of highly specific MSC markers to measure its potency remains an impediment to developing this promising cellular therapeutic. To address this problem, our multidisciplinary team of outstanding biosystem engineers, stem cell biologists and system biologists will elucidate a comprehensive set of markers that can be used to reproducibly and prospectively assess the immune regulatory functions of MSCs. The resulting set of biomarkers will significantly contribute to the development of this promising cellular therapeutic. Sensitive tests to detect the resulting biomarkers can feasibly be performed using standard lab or hospital diagnostic equipment. We will work with our clinical and industrial collaborators to improve the identification of potent MSC cell lots, design highly controlled manufacturing processes to produce clinical-grade MSCs and predict the efficacy of the clinical cell dose with the goal of developing MSC-derived cellular therapeutics to treat Canadians afflicted with diverse immune and inflammatory medical conditions, some of which have no cure.

间充质基质/干细胞（MSC）具有减弱免疫系统的独特能力，因此正在被研究。 作为一种有前景的细胞治疗剂被开发用于治疗多种免疫和炎症疾病如感染性休克， 多发性硬化症和心脏病MSC的功效或效力是可变的，并且缺乏高度特异性的MSC 用于测量其效力的标记物仍然是开发这种有前途的细胞治疗剂的障碍。为了解决这个 问题，我们的多学科团队的杰出生物系统工程师，干细胞生物学家和系统生物学家将 阐明了一套全面的标志物，可用于可重复和前瞻性地评估免疫调节 MSC的功能由此产生的一组生物标志物将大大有助于这种有前途的细胞的发展 有治疗作用的使用标准实验室或医院可以可行地进行检测所得生物标志物的敏感测试 诊断设备。我们将与我们的临床和工业合作者合作，以提高有效的MSC的识别， 细胞批次，设计高度受控的制造工艺来生产临床级MSC，并预测 临床细胞剂量，目标是开发MSC衍生的细胞疗法，以治疗患有多种疾病的加拿大人。 免疫和炎症性疾病，其中一些无法治愈。